Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Quality of life in irritable bowel syndrome: Authors' reply.

Mujagic Z, Weerts ZZRM, Vork L, Leue C, Kruimel JW, Hesselink M, Muris JWM, Jonkers DMAE, Masclee AAM, Keszthelyi D.

Neurogastroenterol Motil. 2020 Jan;32(1):e13729. doi: 10.1111/nmo.13729. No abstract available.

PMID:
31854094
2.

Percutaneous endoscopic versus radiologic gastrostomy for enteral feeding: a retrospective analysis on outcomes and complications.

Strijbos D, Keszthelyi D, Gilissen LPL, Lacko M, Hoeijmakers JGJ, van der Leij C, de Ridder RJJ, de Haan MW, Masclee AAM.

Endosc Int Open. 2019 Nov;7(11):E1487-E1495. doi: 10.1055/a-0953-1524. Epub 2019 Oct 23.

3.

Prucalopride: An Opportunity to Simultaneously Address Gastroparesis and Chronic Constipation.

Keszthelyi D.

Am J Gastroenterol. 2019 Dec;114(12):1919. doi: 10.14309/ajg.0000000000000415. No abstract available.

PMID:
31592785
4.

Normal colonic transit time predicts the outcome of colonic manometry in patients with chronic constipation-an exploratory study.

Vork L, van Avesaat MHP, van Hoboken EA, Kruimel JW, Conchillo JM, Keszthelyi D, Masclee AAM.

Int J Colorectal Dis. 2019 Oct;34(10):1819-1822. doi: 10.1007/s00384-019-03376-1. Epub 2019 Aug 31.

PMID:
31471700
5.

Efficacy and Safety of Peppermint Oil in a Randomized, Double-Blind Trial of Patients With Irritable Bowel Syndrome.

Weerts ZZRM, Masclee AAM, Witteman BJM, Clemens CHM, Winkens B, Brouwers JRBJ, Frijlink HW, Muris JWM, De Wit NJ, Essers BAB, Tack J, Snijkers JTW, Bours AMH, de Ruiter-van der Ploeg AS, Jonkers DMAE, Keszthelyi D.

Gastroenterology. 2020 Jan;158(1):123-136. doi: 10.1053/j.gastro.2019.08.026. Epub 2019 Aug 27.

PMID:
31470006
6.

Miltefosine treatment reduces visceral hypersensitivity in a rat model for irritable bowel syndrome via multiple mechanisms.

Botschuijver S, van Diest SA, van Thiel IAM, Saia RS, Strik AS, Yu Z, Maria-Ferreira D, Welting O, Keszthelyi D, Jennings G, Heinsbroek SEM, Elferink RPO, Schuren FHJ, de Jonge WJ, van den Wijngaard RM.

Sci Rep. 2019 Aug 29;9(1):12530. doi: 10.1038/s41598-019-49096-y.

7.

Reduction in IBS symptom severity is not paralleled by improvement in quality of life in patients with irritable bowel syndrome.

Weerts ZZRM, Vork L, Mujagic Z, Keszthelyi D, Hesselink MAM, Kruimel J, Leue C, Muris JWM, Jonkers DMAE, Masclee AAM.

Neurogastroenterol Motil. 2019 Aug;31(8):e13629. doi: 10.1111/nmo.13629. Epub 2019 May 22.

8.

Therapeutic strategies in gastroparesis: Results of stepwise approach with diet and prokinetics, Gastric Rest, and PEG-J: A retrospective analysis.

Strijbos D, Keszthelyi D, Smeets FGM, Kruimel J, Gilissen LPL, de Ridder R, Conchillo JM, Masclee AAM.

Neurogastroenterol Motil. 2019 Jun;31(6):e13588. doi: 10.1111/nmo.13588. Epub 2019 Apr 4.

9.

Role of TRPV1 and TRPA1 Ion Channels in Inflammatory Bowel Diseases: Potential Therapeutic Targets?

Csekő K, Beckers B, Keszthelyi D, Helyes Z.

Pharmaceuticals (Basel). 2019 Mar 30;12(2). pii: E48. doi: 10.3390/ph12020048. Review.

10.

Intraintestinal Delivery of Tastants Using a Naso-Duodenal-Ileal Catheter Does Not Influence Food Intake or Satiety.

Klaassen T, Alleleyn AME, van Avesaat M, Troost FJ, Keszthelyi D, Masclee AAM.

Nutrients. 2019 Feb 23;11(2). pii: E472. doi: 10.3390/nu11020472.

11.

Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome.

Vich Vila A, Imhann F, Collij V, Jankipersadsing SA, Gurry T, Mujagic Z, Kurilshikov A, Bonder MJ, Jiang X, Tigchelaar EF, Dekens J, Peters V, Voskuil MD, Visschedijk MC, van Dullemen HM, Keszthelyi D, Swertz MA, Franke L, Alberts R, Festen EAM, Dijkstra G, Masclee AAM, Hofker MH, Xavier RJ, Alm EJ, Fu J, Wijmenga C, Jonkers DMAE, Zhernakova A, Weersma RK.

Sci Transl Med. 2018 Dec 19;10(472). pii: eaap8914. doi: 10.1126/scitranslmed.aap8914.

PMID:
30567928
12.

The Experience Sampling Method-Evaluation of treatment effect of escitalopram in IBS with comorbid panic disorder.

Vork L, Mujagic Z, Drukker M, Keszthelyi D, Conchillo JM, Hesselink MAM, van Os J, Masclee AAM, Leue C, Kruimel JW.

Neurogastroenterol Motil. 2019 Jan;31(1):e13515. doi: 10.1111/nmo.13515. Epub 2018 Nov 20.

PMID:
30460734
13.

The Effect of an Encapsulated Nutrient Mixture on Food Intake and Satiety: A Double-Blind Randomized Cross-Over Proof of Concept Study.

Alleleyn AME, van Avesaat M, Ripken D, Bleiel SB, Keszthelyi D, Wilms E, Troost FJ, Hendriks HFJ, Masclee AAM.

Nutrients. 2018 Nov 17;10(11). pii: E1787. doi: 10.3390/nu10111787.

14.

Development of a real-time patient-reported outcome measure for symptom assessment in patients with functional dyspepsia using the experience sampling method.

Smeets FGM, Keszthelyi D, Vork L, Tack J, Talley NJ, Simren M, Aziz Q, Ford AC, Conchillo JM, Kruimel JW, Van Os J, Masclee AAM.

Neurogastroenterol Motil. 2019 Feb;31(2):e13496. doi: 10.1111/nmo.13496. Epub 2018 Nov 4.

PMID:
30393939
15.

A Novel Ileocolonic Release Peppermint Oil Capsule for Treatment of Irritable Bowel Syndrome: A Phase I Study in Healthy Volunteers.

Weerts ZZRM, Keszthelyi D, Vork L, Aendekerk NCP, Frijlink HW, Brouwers JRBJ, Neef C, Jonkers DMAE, Masclee AAM.

Adv Ther. 2018 Nov;35(11):1965-1978. doi: 10.1007/s12325-018-0802-1. Epub 2018 Oct 4.

PMID:
30284674
16.

A Systematic Review and Meta-Analysis on Outcomes and Complications of Percutaneous Endoscopic Versus Radiologic Gastrostomy for Enteral Feeding.

Strijbos D, Keszthelyi D, Bogie RMM, Gilissen LPL, Lacko M, Hoeijmakers JGJ, van der Leij C, de Ridder R, de Haan MW, Masclee AAM.

J Clin Gastroenterol. 2018 Oct;52(9):753-764. doi: 10.1097/MCG.0000000000001082.

PMID:
29924079
17.

Systematic review: Disease-specific instruments to assess gastrointestinal symptoms in functional dyspepsia.

Smeets FGM, Masclee AAM, Conchillo JM, Keszthelyi D.

Neurogastroenterol Motil. 2018 Mar 9. doi: 10.1111/nmo.13327. [Epub ahead of print]

PMID:
29520918
18.

Delineation between different components of chronic pain using dimension reduction - an ASL fMRI study in hand osteoarthritis.

Keszthelyi D, Aziz Q, Ruffle JK, O'Daly O, Sanders D, Krause K, Williams SCR, Howard MA.

Eur J Pain. 2018 Aug;22(7):1245-1254. doi: 10.1002/ejp.1212. Epub 2018 Apr 16.

19.

Percutaneous endoscopic colostomy for adults with chronic constipation: Retrospective case series of 12 patients.

Strijbos D, Keszthelyi D, Masclee AAM, Gilissen LPL.

Neurogastroenterol Motil. 2018 May;30(5):e13270. doi: 10.1111/nmo.13270. Epub 2017 Dec 18.

PMID:
29250849
20.

Letter: the neglected analgesic properties of red pepper in the clinical management of the irritable bowel syndrome pain-Authors' reply.

Beckers AB, Weerts ZZRM, Masclee AAM, Keszthelyi D.

Aliment Pharmacol Ther. 2018 Jan;47(1):154-155. doi: 10.1111/apt.14442. No abstract available.

21.

Development, content validity, and cross-cultural adaptation of a patient-reported outcome measure for real-time symptom assessment in irritable bowel syndrome.

Vork L, Keszthelyi D, Mujagic Z, Kruimel JW, Leue C, Pontén I, Törnblom H, Simrén M, Albu-Soda A, Aziz Q, Corsetti M, Holvoet L, Tack J, Rao SS, van Os J, Quetglas EG, Drossman DA, Masclee AAM.

Neurogastroenterol Motil. 2018 Mar;30(3). doi: 10.1111/nmo.13244. Epub 2017 Nov 6.

PMID:
29106029
22.

Review article: transient receptor potential channels as possible therapeutic targets in irritable bowel syndrome.

Beckers AB, Weerts ZZRM, Helyes Z, Masclee AAM, Keszthelyi D.

Aliment Pharmacol Ther. 2017 Nov;46(10):938-952. doi: 10.1111/apt.14294. Epub 2017 Sep 8. Review.

23.

Percutaneous endoscopic gastrostomy under conscious sedation in patients with amyotrophic lateral sclerosis is safe: an observational study.

Strijbos D, Hofstede J, Keszthelyi D, Masclee AAM, Gilissen LPL.

Eur J Gastroenterol Hepatol. 2017 Nov;29(11):1303-1308. doi: 10.1097/MEG.0000000000000959.

PMID:
28877087
24.

Rome III vs Rome IV criteria for irritable bowel syndrome: A comparison of clinical characteristics in a large cohort study.

Vork L, Weerts ZZRM, Mujagic Z, Kruimel JW, Hesselink MAM, Muris JWM, Keszthelyi D, Jonkers DMAE, Masclee AAM.

Neurogastroenterol Motil. 2018 Feb;30(2). doi: 10.1111/nmo.13189. Epub 2017 Aug 14.

PMID:
28804974
25.

Biomarkers for visceral hypersensitivity in patients with irritable bowel syndrome.

Mujagic Z, Jonkers DMAE, Ludidi S, Keszthelyi D, Hesselink MA, Weerts ZZRM, Kievit RN, Althof JF, Leue C, Kruimel JW, van Schooten FJ, Masclee AAM.

Neurogastroenterol Motil. 2017 Dec;29(12). doi: 10.1111/nmo.13137. Epub 2017 Jul 3.

PMID:
28675524
26.

Editorial: Clinical Implications of Diagnosing Irritable Bowel Syndrome: Do All Roads Need to Lead to Rome?

Keszthelyi D, Ringel Y.

Am J Gastroenterol. 2017 Jun;112(6):900-902. doi: 10.1038/ajg.2017.115.

PMID:
28572651
27.

A magnetic resonance imaging study of gastric motor function in patients with dyspepsia associated with Ehlers-Danlos Syndrome-Hypermobility Type: A feasibility study.

Menys A, Keszthelyi D, Fitzke H, Fikree A, Atkinson D, Aziz Q, Taylor SA.

Neurogastroenterol Motil. 2017 Sep;29(9). doi: 10.1111/nmo.13090. Epub 2017 May 31.

PMID:
28568908
28.

Exploration of the Esophageal Mucosal Barrier in Non-Erosive Reflux Disease.

Rinsma NF, Farré R, Troost FJ, Elizalde M, Keszthelyi D, Helyes Z, Masclee AA, Conchillo JM.

Int J Mol Sci. 2017 May 19;18(5). pii: E1091. doi: 10.3390/ijms18051091.

29.

Gastrointestinal disorders in joint hypermobility syndrome/Ehlers-Danlos syndrome hypermobility type: A review for the gastroenterologist.

Beckers AB, Keszthelyi D, Fikree A, Vork L, Masclee A, Farmer AD, Aziz Q.

Neurogastroenterol Motil. 2017 Aug;29(8). doi: 10.1111/nmo.13013. Epub 2017 Jan 13. Review.

PMID:
28086259
30.

Translational Difficulties in Studying the TRPA1 Receptor.

Keszthelyi D, van Avesaat M, Troost FJ, Masclee AA.

Nutrients. 2016 Dec 3;8(12). pii: E790.

31.

Tricyclic Antidepressants: What to Choose and Which Dose?

Keszthelyi D, Masclee AA.

Am J Gastroenterol. 2016 Jul;111(7):1035-6. doi: 10.1038/ajg.2016.104. No abstract available.

PMID:
27356830
32.

Editorial: serotonin and irritable bowel syndrome--reconciling pharmacological effects with basic biology; authors' reply.

Mujagic Z, Keszthelyi D, Thijssen AY, Jonkers DM, Masclee AA.

Aliment Pharmacol Ther. 2016 Mar;43(5):646-7. doi: 10.1111/apt.13506. No abstract available.

33.

Capsaicin-induced satiety is associated with gastrointestinal distress but not with the release of satiety hormones.

van Avesaat M, Troost FJ, Westerterp-Plantenga MS, Helyes Z, Le Roux CW, Dekker J, Masclee AA, Keszthelyi D.

Am J Clin Nutr. 2016 Feb;103(2):305-13. doi: 10.3945/ajcn.115.123414. Epub 2015 Dec 30.

PMID:
26718419
34.

Dilation in achalasia - is normal distensibility enough: Author's reply.

Smeets FG, Masclee AA, Keszthelyi D, Tjwa ET, Conchillo JM.

Neurogastroenterol Motil. 2016 Jan;28(1):154-5. doi: 10.1111/nmo.12729. No abstract available.

PMID:
26690874
35.

Update on pathogenesis and predictors of response of therapeutic strategies used in inflammatory bowel disease.

Quetglas EG, Mujagic Z, Wigge S, Keszthelyi D, Wachten S, Masclee A, Reinisch W.

World J Gastroenterol. 2015 Nov 28;21(44):12519-43. doi: 10.3748/wjg.v21.i44.12519. Review.

36.

Alterations in serotonin metabolism in the irritable bowel syndrome.

Thijssen AY, Mujagic Z, Jonkers DM, Ludidi S, Keszthelyi D, Hesselink MA, Clemens CH, Conchillo JM, Kruimel JW, Masclee AA.

Aliment Pharmacol Ther. 2016 Jan;43(2):272-82. doi: 10.1111/apt.13459. Epub 2015 Nov 5.

37.

Systematic review: instruments to assess abdominal pain in irritable bowel syndrome.

Mujagic Z, Keszthelyi D, Aziz Q, Reinisch W, Quetglas EG, De Leonardis F, Segerdahl M, Masclee AA.

Aliment Pharmacol Ther. 2015 Nov;42(9):1064-81. doi: 10.1111/apt.13378. Epub 2015 Aug 20. Review.

38.

Esophagogastric junction distensibility in the management of achalasia patients: relation to treatment outcome.

Smeets FG, Masclee AA, Keszthelyi D, Tjwa ET, Conchillo JM.

Neurogastroenterol Motil. 2015 Oct;27(10):1495-503. doi: 10.1111/nmo.12651. Epub 2015 Aug 12.

PMID:
26264119
39.

Measurement of Esophagogastric Junction Distensibility May Assist in Selecting Patients for Endoluminal Gastroesophageal Reflux Disease Surgery: Author's Reply.

Smeets FG, Keszthelyi D, Masclee AA, Conchillo JM.

J Neurogastroenterol Motil. 2015 Jul 30;21(3):450-1. doi: 10.5056/jnm15101. No abstract available.

40.

The Experience Sampling Method--a new digital tool for momentary symptom assessment in IBS: an exploratory study.

Mujagic Z, Leue C, Vork L, Lousberg R, Jonkers DM, Keszthelyi D, Hesselink MA, van Schagen TJ, van Os J, Masclee AA, Kruimel JW.

Neurogastroenterol Motil. 2015 Sep;27(9):1295-302. doi: 10.1111/nmo.12624. Epub 2015 Jun 22.

PMID:
26100684
41.

Visceral hypersensitivity in irritable bowel syndrome: evidence for involvement of serotonin metabolism--a preliminary study.

Keszthelyi D, Troost FJ, Jonkers DM, van Eijk HM, Dekker J, Buurman WA, Masclee AA.

Neurogastroenterol Motil. 2015 Aug;27(8):1127-37. doi: 10.1111/nmo.12600. Epub 2015 May 31.

PMID:
26031193
42.

Does Measurement of Esophagogastric Junction Distensibility by EndoFLIP Predict Therapy- responsiveness to Endoluminal Fundoplication in Patients With Gastroesophageal Reflux Disease?

Smeets FG, Keszthelyi D, Bouvy ND, Masclee AA, Conchillo JM.

J Neurogastroenterol Motil. 2015 Mar 30;21(2):255-64. doi: 10.5056/jnm14111.

43.

Incidence of microscopic colitis in the Netherlands. A nationwide population-based study from 2000 to 2012.

Verhaegh BP, Jonkers DM, Driessen A, Zeegers MP, Keszthelyi D, Masclee AA, Pierik MJ.

Dig Liver Dis. 2015 Jan;47(1):30-6. doi: 10.1016/j.dld.2014.09.019. Epub 2014 Dec 18.

PMID:
25455154
44.

Ethanol impairs intestinal barrier function in humans through mitogen activated protein kinase signaling: a combined in vivo and in vitro approach.

Elamin E, Masclee A, Troost F, Pieters HJ, Keszthelyi D, Aleksa K, Dekker J, Jonkers D.

PLoS One. 2014 Sep 16;9(9):e107421. doi: 10.1371/journal.pone.0107421. eCollection 2014.

45.

Capsaicin stimulation in irritable bowel syndrome: toward understanding visceral perception and pain symptom generation.

Keszthelyi D, Masclee A.

Am J Gastroenterol. 2014 Aug;109(8):1286. doi: 10.1038/ajg.2014.135. No abstract available.

PMID:
25091243
46.

Serotonergic reinforcement of intestinal barrier function is impaired in irritable bowel syndrome.

Keszthelyi D, Troost FJ, Jonkers DM, van Eijk HM, Lindsey PJ, Dekker J, Buurman WA, Masclee AA.

Aliment Pharmacol Ther. 2014 Aug;40(4):392-402. doi: 10.1111/apt.12842. Epub 2014 Jun 18.

47.

Small intestinal permeability is increased in diarrhoea predominant IBS, while alterations in gastroduodenal permeability in all IBS subtypes are largely attributable to confounders.

Mujagic Z, Ludidi S, Keszthelyi D, Hesselink MA, Kruimel JW, Lenaerts K, Hanssen NM, Conchillo JM, Jonkers DM, Masclee AA.

Aliment Pharmacol Ther. 2014 Aug;40(3):288-97. doi: 10.1111/apt.12829. Epub 2014 Jun 18.

48.

Markers for visceral hypersensitivity in patients with irritable bowel syndrome.

Ludidi S, Mujagic Z, Jonkers D, Keszthelyi D, Hesselink M, Kruimel J, Conchillo J, Masclee A.

Neurogastroenterol Motil. 2014 Aug;26(8):1104-11. doi: 10.1111/nmo.12365. Epub 2014 Jun 11.

PMID:
24920528
49.

Letter: the role of sub-clinical inflammation and TRPV1 in the development of IBS-like symptoms in ulcerative colitis in remission.

Keszthelyi D, Jonkers DM, Hamer HM, Masclee AA.

Aliment Pharmacol Ther. 2013 Sep;38(5):560-1. doi: 10.1111/apt.12409. No abstract available.

50.

Letter: lansoprazole consumption is more common in Japanese patients with collagenous colitis--authors' reply.

Keszthelyi D, Masclee AA.

Aliment Pharmacol Ther. 2013 Jul;38(2):209-10. doi: 10.1111/apt.12364. No abstract available.

Supplemental Content

Loading ...
Support Center